Reply to the enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic

"Reply to the enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic." Human Vaccines & Immunotherapeutics, 20(1), pp.

View responses to this article:

Regarding “Reply to the enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic”

Disclosure statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

Funding

This manuscript was funded by the Jiangsu Health Development Research Center Open Project [grant number JSHD2022043], the Jiangsu Provincial Geriatric Health Research Project [grant number LKM2023005], Suqian Sci&Tech Program [grant number SY202312] and Jiangsu Provincial Health Commission Preventive Medicine and Hematology Prevention Research Project [grant number Ym2023099].